05 Mar How Best to Measure Patient Persistence with Medications? Self Report or Pharmacy Fill?
Posted at 02:29h
in Author Interviews, Compliance, Electronic Records, JAMA, University of Pennsylvania
MedicalResearch.com Interview with:
[caption id="attachment_53388" align="alignleft" width="180"]
Dr. Fanaroll[/caption]
Alexander C. Fanaroff, MD, MHS
Assistant Professor of Medicine, Division of Cardiovascular Medicine
University of Pennsylvania
MedicalResearch.com: What is the background for this study?
Response: This is a secondary analysis of the ARTEMIS, a cluster randomized trial of copayment assistance for P2Y12 inhibitors in patients that had myocardial infarction. One of the primary endpoints of ARTEMIS was persistence with P2Y12 inhibitors: Did the patient continue to take a P2Y12 inhibitor over the entire 1 year following MI? In ARTEMIS, we captured persistence data in two ways, patient report and pharmacy fill records. What we did in this study was to look at the agreement between persistence as measured by these two methods.

Prof. Woloshin[/caption]
Steven Woloshin, MD, MS
Professor of Medicine and Community and Family Medicine
Professor, The Dartmouth Institute for Health Policy and Clinical Practice
MedicalResearch.com: What is the background for this study?
Response: Industry spends more on detailing visits and free samples than any other form of prescription drug marketing. There is good evidence that these activities can lead to more use of expensive new drugs over equally effective cheaper options. Given these concerns there have been efforts by some hospitalls and practices to restrict these forms of marketing.
We asked physicians in group practices delivering primary care about how often pharmaceutical reps visit their practice and whether they have a free sample closet.